Explore proposed legislation aiming to cap insulin costs at $35, addressing financial burdens on families managing diabetes. Current healthcare challenges assessed.

Study from OHSU links health insurance loss to poor diabetes management, urging improved support for community health and Medicaid policy reform.

Explore how recent federal policy changes enhance access to the Medicare Diabetes Prevention Program, promoting health for older adults at risk of diabetes.

Discover a rise in CGM adoption among Medicare enrollees with diabetes, enhancing management and access by 2026 with no out-of-pocket costs.

Discover how life insurance underwriting for diabetics has evolved, including new rates and criteria that benefit well-managed diabetes patients.

Discover ECU Health's diabetes program empowering individuals with practical self-care strategies for better lifestyle management. Enroll today!

Eli Lilly's diabetes drug Mounjaro is set to be included in China's national health insurance reimbursement list, boosting accessibility but with potential revenue impact from pricing adjustments.

In 2021-2022, diabetes treatment costs in the U.S. totaled $153.2 billion, driven largely by Medicare and private insurance coverage, according to AHRQ MEPS data.

Eli Lilly's Mounjaro joins China's national health insurance list for type 2 diabetes, enhancing accessibility amid pricing adjustments. Related diabetes therapies and market impacts examined.

AdvaMed responds to CMS 2026 payment rule, stressing patient access to diabetes and prosthetic supplies amid competitive bidding concerns.